secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001193125-24-125073
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)
--------------------------------------------------------------------------------

- Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.
- GAAP net income $9M vs loss of $5M in prior year; Adjusted EBITDA $19M (22% margin) vs $5.5M (7.7%).
- Cash $48M at March 31, down from $82M at Dec 31, due to repaying $30M revolver and $5M TELA Bio payment.
- Signed distribution agreement with Regenity Biosciences for 510(k)-cleared collagen xenograft; launch expected later in 2024.
- Appointed two new independent directors; launched MIMEDX Connect online ordering platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/0001193125-24-125073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/d832294d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-125073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer